NCT01842308View on ClinicalTrials.gov

Carfilzomib and Melphalan Before Stem Cell Transplant in Treating Patients With Multiple Myeloma

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

June 4, 2013

Primary Completion Date

October 11, 2017

Study Completion Date

October 28, 2019

Conditions
DS Stage I Plasma Cell MyelomaDS Stage II Plasma Cell MyelomaDS Stage III Plasma Cell MyelomaRefractory Plasma Cell Myeloma
Interventions
PROCEDURE

Autologous Bone Marrow Transplantation

Undergo autologous stem cell transplant

PROCEDURE

Autologous Hematopoietic Stem Cell Transplantation

Undergo autologous stem cell transplant

DRUG

Carfilzomib

Given IV

OTHER

Laboratory Biomarker Analysis

Correlative studies

DRUG

Melphalan

Given IV

Trial Locations (2)

55905

Mayo Clinic, Rochester

32224-9980

Mayo Clinic in Florida, Jacksonville

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Mayo Clinic

OTHER

NCT01842308 - Carfilzomib and Melphalan Before Stem Cell Transplant in Treating Patients With Multiple Myeloma | Biotech Hunter | Biotech Hunter